Type 1 diabetes diagnostic tests
Pro Research Analysisby 
Searched over 200M research papers
Key Diagnostic Tests for Type 1 Diabetes
Type 1 diabetes (T1D) diagnosis relies on a combination of clinical features, laboratory tests, and biomarkers. The main diagnostic approaches include blood glucose testing, islet autoantibody detection, C-peptide measurement, and emerging molecular biomarkers.
Oral Glucose Tolerance Test (OGTT) and Risk Scores
The OGTT is a standard test for diagnosing diabetes, including T1D. Traditionally, a 2-hour OGTT is used, but recent research shows that a 1-hour OGTT can predict T1D just as accurately, making it a faster and more cost-effective option. The 1-hour OGTT, when combined with other measures like fasting C-peptide, age, and BMI, provides a reliable risk score for T1D diagnosis and surveillance, with high predictive value and minimal risk of missing a diagnosis before the next clinical visit .
Additionally, composite indices such as Index60, which combines glucose and C-peptide measurements, can identify individuals at high risk for T1D even when traditional OGTT criteria are not met. These indices may capture cases that would otherwise be missed and are associated with typical T1D characteristics and high progression rates to clinical diabetes . Metabolic tests and risk indices derived from OGTT data are also valuable for tracking beta cell function and disease progression, especially in preclinical stages .
Islet Autoantibody Testing
Detection of islet autoantibodies (such as GADA and Islet Antigen 2) is a cornerstone for diagnosing T1D, especially in distinguishing it from type 2 diabetes. The presence of these autoantibodies confirms autoimmune destruction of beta cells and is recommended when T1D is clinically suspected or when there is rapid progression to insulin therapy after a type 2 diabetes diagnosis Thomas2023Bonifacio2025Bonifacio2015. Islet autoantibody testing is particularly important in the presymptomatic phase, as it can identify individuals at risk before clinical symptoms appear Bonifacio2025Bonifacio2015.
C-Peptide Measurement
C-peptide is a marker of endogenous insulin production. Low C-peptide levels indicate severe insulin deficiency, which is characteristic of T1D. C-peptide testing is used to confirm the diagnosis, especially in adults where distinguishing between T1D and type 2 diabetes can be challenging Lynam2019Thomas2023. C-peptide measurements are also useful for staging the disease and monitoring beta cell function over time .
Multivariable Clinical Diagnostic Models
Combining clinical features (such as age at diagnosis and BMI) with biomarkers (islet autoantibodies, C-peptide, and genetic risk scores) in multivariable models significantly improves diagnostic accuracy. These models can distinguish T1D from type 2 diabetes with high precision and are validated in both clinical and research settings Lynam2019Carr2020.
Emerging Molecular Biomarkers
Recent studies have identified novel blood-based biomarkers, such as specific circular RNAs (hsa_circRNA_405498 and hsa_circRNA_100033), which show high accuracy in differentiating T1D from other forms of diabetes and healthy controls. These molecular markers, when combined with clinical parameters, offer promising new tools for differential diagnosis Zhang2023Cabrera2016.
Conclusion
Diagnosing type 1 diabetes involves a combination of clinical assessment, OGTT (including 1-hour and 2-hour protocols), islet autoantibody testing, C-peptide measurement, and, increasingly, advanced molecular biomarkers. Integrating these tests—especially through multivariable models—improves diagnostic accuracy, helps distinguish T1D from other diabetes types, and enables earlier detection and intervention. Ongoing research continues to refine these approaches, aiming for more precise and accessible diagnostic tools for all age groups.
Sources and full results
Most relevant research papers on this topic